- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.09. | Conexeu Sciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.08. | Conexeu Sciences Inc.: Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration | 3 | GlobeNewswire (USA) | ||
| 14.07. | Conexeu Sciences Inc.: The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It | 1 | GlobeNewswire (USA) | ||
| 09.07. | One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics | 4 | CNW | ||
| 07.07. | Conexeu Sciences Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| CONEXEU SCIENCES Aktie jetzt für 0€ handeln | |||||
| 07.07. | Conexeu Sciences Inc.: A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill | 1 | GlobeNewswire (USA) | ||
| 25.06. | Conexeu Sciences Inc.: Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform | 1 | GlobeNewswire (USA) | ||
| 22.06. | Conexeu Sciences stock initiated at buy by H.C. Wainwright, $20 target | 1 | Investing.com | ||
| 15.06. | Conexeu Sciences Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.06. | Conexeu Sciences Inc.: Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing | 270 | GlobeNewswire (Europe) | RENO, Nev., June 15, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, today announced additions to... ► Artikel lesen | |
| 09.06. | Conexeu Sciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Conexeu Sciences: Aktie legt nach Fortschritten bei Wundversorgungs-Produkt zu | 1 | Investing.com Deutsch | ||
| 08.06. | Conexeu forciert Produktionsaufbau für Wundpflege-Produkt vor geplantem FDA-Antrag 2027 | - | Investing.com Deutsch | ||
| 08.06. | Conexeu Sciences Inc.: Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU Wound Care Program | 1 | GlobeNewswire (USA) | ||
| 03.06. | Conexeu Sciences Inc.: Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026 | 1 | GlobeNewswire (USA) | ||
| 21.05. | Conexeu Sciences Inc.: Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU" | 556 | Newsfile | Reno, Nevada--(Newsfile Corp. - May 21, 2026) - Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, announced it has officially... ► Artikel lesen | |
| 19.05. | Conexeu Sciences Inc.: Conexeu Sciences Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants | 565 | Newsfile | Conexeu's B.R.E.A.S.T. was developed using the Company's proprietary CXU regenerative tissue platform to support gradual tissue remodelingDesigned as a resorbable, bioregenerative tissue matrix... ► Artikel lesen | |
| 14.05. | Conexeu Sciences Inc.: Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration | 513 | Newsfile | Reno, Nevada--(Newsfile Corp. - May 14, 2026) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a medical device company advancing regenerative medicine through its patented bioregenerative extracellular... ► Artikel lesen | |
| 12.05. | Medical device developer Conexeu Sciences set to direct list on the Nasdaq on May 21 | 1 | Renaissance Capital | ||
| 11.05. | Conexeu Sciences Inc. - 8-A12B, Registration of securities | - | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,460 | -0,36 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,068 | +5,26 % | Dr. Steven S. Sangha: Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc. | Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection... ► Artikel lesen | |
| CERENOME | 1,744 | -0,57 % | Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,060 | +5,10 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | +1,36 % | Tandem Diabetes Care, Inc.: Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets | Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,970 | +2,57 % | Co-Diagnostics, Inc. - 8-K, Current Report | ||
| QUIDELORTHO | 9,076 | -1,99 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,395 | -0,62 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 7,030 | -1,82 % | Lifeward legt Termin für jährliche und außerordentliche Hauptversammlung 2026 fest | ||
| CLOVER HEALTH INVESTMENTS | 3,920 | +1,03 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| SENSEONICS | 7,850 | -5,99 % | Senseonics sees activist investor take a major stake | ||
| TEMPEST THERAPEUTICS | 0,965 | -0,35 % | Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform | -Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in... ► Artikel lesen | |
| NANO-X IMAGING | 0,745 | +1,54 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| IMUNON | 1,220 | 0,00 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |
Das Unternehmen CONEXEU SCIENCES INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,960 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CONEXEU SCIENCES INC finden Sie auf Wallstreet Online.